Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
07 Jun 2024
07 Jun 2024
Historique:
received:
09
01
2024
accepted:
28
05
2024
revised:
15
05
2024
medline:
8
6
2024
pubmed:
8
6
2024
entrez:
7
6
2024
Statut:
aheadofprint
Résumé
This study aims to determine whether 1) individuals with treatment-resistant schizophrenia display early cognitive impairment compared to treatment-responders and healthy controls and 2) N-methyl-D-aspartate-receptor hypofunction is an underlying mechanism of cognitive deficits in treatment-resistance. In this case‒control 3-year-follow-up longitudinal study, n = 697 patients with first-episode psychosis, aged 18 to 35, were screened for Treatment Response and Resistance in Psychosis criteria through an algorithm that assigns patients to responder, limited-response or treatment-resistant category (respectively resistant to 0, 1 or 2 antipsychotics). Assessments at baseline: MATRICS Consensus Cognitive Battery; N-methyl-D-aspartate-receptor co-agonists biomarkers in brain by MRS (prefrontal glutamate levels) and plasma (D-serine and glutamate pathways key markers). Patients were compared to age- and sex-matched healthy controls (n = 114). Results: patient mean age 23, 27% female. Treatment-resistant (n = 51) showed lower scores than responders (n = 183) in processing speed, attention/vigilance, working memory, verbal learning and visual learning. Limited responders (n = 59) displayed an intermediary phenotype. Treatment-resistant and limited responders were merged in one group for the subsequent D-serine and glutamate pathway analyses. This group showed D-serine pathway dysregulation, with lower levels of the enzymes serine racemase and serine-hydroxymethyltransferase 1, and higher levels of the glutamate-cysteine transporter 3 than in responders. Better cognition was associated with higher D-serine and lower glutamate-cysteine transporter 3 levels only in responders; this association was disrupted in the treatment resistant group. Treatment resistant patients and limited responders displayed early cognitive and persistent functioning impairment. The dysregulation of NMDAR co-agonist pathways provides underlying molecular mechanisms for cognitive deficits in treatment-resistant first-episode psychosis. If replicated, our findings would open ways to mechanistic biomarkers guiding response-based patient stratification and targeting cognitive improvement in clinical trials.
Identifiants
pubmed: 38849515
doi: 10.1038/s41380-024-02631-4
pii: 10.1038/s41380-024-02631-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Elkis H. Treatment-Resistant Schizophrenia. Psychiatr Clin North Am. 2007;30:511–33.
pubmed: 17720034
doi: 10.1016/j.psc.2007.04.001
Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, et al. Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;65:34–48.
doi: 10.1016/j.pnpbp.2015.08.010
Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry. 2017;174:216–29.
pubmed: 27919182
doi: 10.1176/appi.ajp.2016.16050503
Kravariti E, Demjaha A, Zanelli J, Ibrahim F, Wise C, MacCabe JH, et al. Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study. Psychol Med. 2019;49:2100–10.
pubmed: 30348234
doi: 10.1017/S0033291718002957
Yada Y, Yoshimura B, Kishi Y. Correlation between delay in initiating clozapine and symptomatic improvement. Schizophrenia Res. 2015;168:585–6.
doi: 10.1016/j.schres.2015.07.045
Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer J-P, Marder S, et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. J Clin Psychiatry. 2019;80:18com12123.
pubmed: 30840788
doi: 10.4088/JCP.18com12123
Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64:30–4.
pubmed: 12590620
doi: 10.4088/JCP.v64n0107
Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship Between Duration of Untreated Psychosis and Outcome in First-Episode Schizophrenia: A Critical Review and Meta-Analysis. Am J Psychiatry. 2005;162:1785–804.
pubmed: 16199825
doi: 10.1176/appi.ajp.162.10.1785
Agid O, Remington G, Kapur S, Arenovich T, Zipursky RB. Early Use of Clozapine for Poorly Responding First-Episode Psychosis. J Clin Psychopharmacol. 2007;27:369–73.
pubmed: 17632221
doi: 10.1097/jcp.0b013e3180d0a6d4
Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia. Neuropsychopharmacology. 2012;37:2515–21.
pubmed: 22763619
pmcid: 3442346
doi: 10.1038/npp.2012.113
Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, et al. Antipsychotic Treatment Resistance in Schizophrenia Associated with Elevated Glutamate Levels but Normal Dopamine Function. Biol Psychiatry. 2014;75:e11–3.
pubmed: 23890739
doi: 10.1016/j.biopsych.2013.06.011
Mouchlianitis E, Bloomfield MAP, Law V, Beck K, Selvaraj S, Rasquinha N, et al. Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive. Schizophrenia Bull. 2016;42:744–52.
doi: 10.1093/schbul/sbv151
Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145–55.
pubmed: 29880882
doi: 10.1038/s41380-018-0082-9
Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73:204–15.
pubmed: 30666759
doi: 10.1111/pcn.12823
Bendikov I, Nadri C, Amar S, Panizzutti R, Demiranda J, Wolosker H, et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophrenia Res. 2007;90:41–51.
doi: 10.1016/j.schres.2006.10.010
Egerton A, Griffiths K, Casetta C, Deakin B, Drake R, Howes OD, et al. Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration. Neuropsychopharmacology. 2022;48:567–75.
pubmed: 36456813
pmcid: 9852590
doi: 10.1038/s41386-022-01508-w
McCullumsmith R. Striatal Excitatory Amino Acid Transporter Transcript Expression in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. Neuropsychopharmacology. 2002;26:368–75.
pubmed: 11850151
doi: 10.1016/S0893-133X(01)00370-0
Afshari P, Myles-Worsley M, Cohen OS, Tiobech J, Faraone SV, Byerley W, et al. Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia. Complex Psychiatry. 2015;1:125–44.
doi: 10.1159/000433599
Bjørn-Yoshimoto WE, Underhill SM. The importance of the excitatory amino acid transporter 3 (EAAT3). Neurochemistry Int. 2016;98:4–18.
doi: 10.1016/j.neuint.2016.05.007
Underhill SM, Ingram SL, Ahmari SE, Veenstra-VanderWeele J, Amara SG. Neuronal excitatory amino acid transporter EAAT3: Emerging functions in health and disease. Neurochemistry Int. 2019;123:69–76.
doi: 10.1016/j.neuint.2018.05.012
Radhakrishnan S, Amara SG Cellular redox regulation by the neuronal glutamate and cysteine transporter, EAAT3. The FASEB Journal. 2022;36:fasebj.2022.36.S1.L7661.
Yamada K, Ohnishi T, Hashimoto K, Ohba H, Iwayama-Shigeno Y, Toyoshima M, et al. Identification of Multiple Serine Racemase (SRR) mRNA Isoforms and Genetic Analyses of SRR and DAO in Schizophrenia and d-Serine Levels. Biol Psychiatry. 2005;57:1493–503.
pubmed: 15953485
doi: 10.1016/j.biopsych.2005.03.018
Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M. Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2005;29:767–9.
doi: 10.1016/j.pnpbp.2005.04.023
Goltsov AY, Loseva JG, Andreeva TV, Grigorenko AP, Abramova LI, Kaleda VG, et al. Polymorphism in the 5′-promoter region of serine racemase gene in schizophrenia. Mol Psychiatry. 2006;11:325–6.
pubmed: 16446740
doi: 10.1038/sj.mp.4001801
Tomiya M, Fukushima T, Watanabe H, Fukami G, Fujisaki M, Iyo M, et al. Alterations in serum amino acid concentrations in male and female schizophrenic patients. Clin Chim Acta. 2007;380:186–90.
pubmed: 17367771
doi: 10.1016/j.cca.2007.02.011
Morita Y, Ujike H, Tanaka Y, Otani K, Kishimoto M, Morio A, et al. A Genetic Variant of the Serine Racemase Gene Is Associated with Schizophrenia. Biol Psychiatry. 2007;61:1200–3.
pubmed: 17067558
doi: 10.1016/j.biopsych.2006.07.025
Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, et al. Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:1905–12.
doi: 10.1016/j.pnpbp.2008.07.022
Hons J, Zirko R, Ulrychova M, Cermakova E, Doubek P, Libiger J. Glycine serum level in schizophrenia: Relation to negative symptoms. Psychiatry Res. 2010;176:103–8.
pubmed: 20096465
doi: 10.1016/j.psychres.2009.11.008
Labrie V, Wong AHC, Roder JC. Contributions of the d-serine pathway to schizophrenia. Neuropharmacology. 2012;62:1484–503.
pubmed: 21295046
doi: 10.1016/j.neuropharm.2011.01.030
Coyle JT, Ruzicka WB, Balu DT. Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse. Am J Psychiatry. 2020;177:1119–28.
pubmed: 33256439
pmcid: 8011846
doi: 10.1176/appi.ajp.2020.20101481
Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca B, Maj M. Plasma Concentrations of Amino Acids in Chronic Schizophrenics Treated with Clozapine. Neuropsychobiology. 2001;44:167–71.
pubmed: 11702015
doi: 10.1159/000054937
Yamamori H, Hashimoto R, Fujita Y, Numata S, Yasuda Y, Fujimoto M, et al. Changes in plasma d-serine, l-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment. Neurosci Lett. 2014;582:93–8.
pubmed: 25218715
doi: 10.1016/j.neulet.2014.08.052
Heresco-Levy U. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27:1113–23.
doi: 10.1016/j.pnpbp.2003.09.007
Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol. 2009;12:45.
pubmed: 18593507
doi: 10.1017/S1461145708009085
Giardino L, Bortolotti F, Orazzo C, Pozza M, Monteleone P, Calzà L, et al. Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas. Brain Res. 1997;762:216–8.
pubmed: 9262176
doi: 10.1016/S0006-8993(97)00478-2
Akkouh IA, Hribkova H, Grabiec M, Budinska E, Szabo A, Kasparek T, et al. Derivation and Molecular Characterization of a Morphological Subpopulation of Human iPSC Astrocytes Reveal a Potential Role in Schizophrenia and Clozapine Response. Schizophrenia Bull. 2022;48:190–8.
doi: 10.1093/schbul/sbab092
Hribkova H, Svoboda O, Bartecku E, Zelinkova J, Horinkova J, Lacinova L, et al. Clozapine Reverses Dysfunction of Glutamatergic Neurons Derived From Clozapine-Responsive Schizophrenia Patients. Front Cell Neurosci. 2022;16:830757.
pubmed: 35281293
pmcid: 8904748
doi: 10.3389/fncel.2022.830757
Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005;10:275–87.
pubmed: 15278098
doi: 10.1038/sj.mp.4001552
Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:1628–30.
pubmed: 8942463
doi: 10.1176/ajp.153.12.1628
Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JTD-. serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999;156:1822–5.
pubmed: 10553752
doi: 10.1176/ajp.156.11.1822
Baumann PS, Crespi S, Marion-Veyron R, Solida A, Thonney J, Favrod J, et al. Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne): implementation of an early intervention programme for psychosis in Switzerland: Early Psychosis intervention in Lausanne. Early Intervention Psychiatry. 2013;7:322–8.
doi: 10.1111/eip.12037
Preisig M, Fenton BT, Matthey M-L, Berney A, Ferrero F. Diagnostic interview for genetic studies (DIGS): inter-rater and test-retest reliability of the French version. Eur Arch Psychiatry Clin Neurosci. 1999;249:174–9.
pubmed: 10449592
doi: 10.1007/s004060050084
Startup M, Jackson MC, Bendix S. The concurrent validity of the Global Assessment of Functioning (GAF). Br J Clin Psychol. 2002;41:417–22.
pubmed: 12437796
doi: 10.1348/014466502760387533
Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N, Delacrétaz A, Choong E, Solida-Tozzi A, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry. 2015;76:e1417–23.
pubmed: 26646038
doi: 10.4088/JCP.14m09358
Vehof J, Risselada AJ, Al Hadithy AF, Burger H, Snieder H, Wilffert B, et al. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacol (Berl). 2011;216:257–65.
doi: 10.1007/s00213-011-2211-x
Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry. 2011;44:195–235.
pubmed: 22053351
doi: 10.1055/s-0031-1286287
Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, et al. The MATRICS Consensus Cognitive Battery, Part 2: Co-Norming and Standardization. Am J Psychiatry. 2008;165:214–20.
pubmed: 18172018
doi: 10.1176/appi.ajp.2007.07010043
Khadimallah I, Jenni R, Cabungcal J-H, Cleusix M, Fournier M, Beard E, et al. Mitochondrial, exosomal miR137-COX6A2 and gamma synchrony as biomarkers of parvalbumin interneurons, psychopathology, and neurocognition in schizophrenia. Mol Psychiatry. 2022;27:1192–204.
pubmed: 34686767
doi: 10.1038/s41380-021-01313-9
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–13.
pubmed: 18172019
doi: 10.1176/appi.ajp.2007.07010042
Xin L, Mekle R, Fournier M, Baumann PS, Ferrari C, Alameda L, et al. Genetic Polymorphism Associated Prefrontal Glutathione and Its Coupling With Brain Glutamate and Peripheral Redox Status in Early Psychosis. Schizophrenia Bull. 2016;42:1185–96.
doi: 10.1093/schbul/sbw038
Gruetter R. Automatic, localized in vivo adjustment of all first- and second-order shim coils. Magn Reson Med. 1993;29:804–11.
pubmed: 8350724
doi: 10.1002/mrm.1910290613
Mekle R, Mlynárik V, Gambarota G, Hergt M, Krueger G, Gruetter R. MR spectroscopy of the human brain with enhanced signal intensity at ultrashort echo times on a clinical platform at 3T and 7T. Magn Reson Med. 2009;61:1279–85.
pubmed: 19319893
doi: 10.1002/mrm.21961
Golay P, Baumann PS, Jenni R, Do KQ, Conus P. Patients participating to neurobiological research in early psychosis: A selected subgroup? Schizophr Res. 2018;201:249–53.
pubmed: 29705004
doi: 10.1016/j.schres.2018.04.033
Thomas M, Szentgyorgyi T, Vanes LD, Mouchlianitis E, Barry EF, Patel K, et al. Cognitive performance in early, treatment-resistant psychosis patients: Could cognitive control play a role in persistent symptoms? Psychiatry Res. 2021;295:113607.
pubmed: 33285345
doi: 10.1016/j.psychres.2020.113607
Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–30.
pubmed: 8610818
doi: 10.1176/ajp.153.3.321
Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Res. 2004;72:41–51.
doi: 10.1016/j.schres.2004.09.009
Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65:1–105.
pubmed: 11369436
doi: 10.1016/S0301-0082(00)00067-8
Uhlhaas PJ, Singer W. Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010;11:100–13.
pubmed: 20087360
doi: 10.1038/nrn2774
Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, Pantazopoulos H, et al. Hippocampal interneurons are abnormal in schizophrenia. Schizophrenia Res. 2011;131:165–73.
doi: 10.1016/j.schres.2011.06.007
Hu H, Gan J, Jonas P. Fast-spiking, parvalbumin
pubmed: 25082707
doi: 10.1126/science.1255263
Hirano Y, Uhlhaas PJ. Current findings and perspectives on aberrant neural oscillations in schizophrenia. Psychiatry Clin Neurosci. 2021;75:358–68.
pubmed: 34558155
doi: 10.1111/pcn.13300
Lodge DJ, Behrens MM, Grace AA. A Loss of Parvalbumin-Containing Interneurons Is Associated with Diminished Oscillatory Activity in an Animal Model of Schizophrenia. J Neurosci. 2009;29:2344–54.
pubmed: 19244511
pmcid: 2754752
doi: 10.1523/JNEUROSCI.5419-08.2009
Sohal VS, Zhang F, Yizhar O, Deisseroth K. Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459:698–702.
pubmed: 19396159
pmcid: 3969859
doi: 10.1038/nature07991
Kim H, Ährlund-Richter S, Wang X, Deisseroth K, Carlén M. Prefrontal Parvalbumin Neurons in Control of Attention. Cell. 2016;164:208–18.
pubmed: 26771492
pmcid: 4715187
doi: 10.1016/j.cell.2015.11.038
Steullet P, Cabungcal J-H, Coyle J, Didriksen M, Gill K, Grace AA, et al. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. Mol Psychiatry. 2017;22:936–43.
pubmed: 28322275
pmcid: 5491690
doi: 10.1038/mp.2017.47
Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? Schizophrenia Res. 2016;176:41–51.
doi: 10.1016/j.schres.2014.06.021
Cuenod M, Steullet P, Cabungcal J-H, Dwir D, Khadimallah I, Klauser P, et al. Caught in vicious circles: a perspective on dynamic feed-forward loops driving oxidative stress in schizophrenia. Mol Psychiatry. 2022;27:1886–97.
pubmed: 34759358
doi: 10.1038/s41380-021-01374-w
Hardingham GE, Do KQ. Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci. 2016;17:125–34.
pubmed: 26763624
doi: 10.1038/nrn.2015.19
Perkins DO, Jeffries CD, Do KQ. Potential Roles of Redox Dysregulation in the Development of Schizophrenia. Biol Psychiatry. 2020;88:326–36.
pubmed: 32560962
pmcid: 7395886
doi: 10.1016/j.biopsych.2020.03.016
Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective Cognitive Impairments Associated with NMDA Receptor Blockade in Humans. Neuropsychopharmacology. 2005;30:633–9.
pubmed: 15647751
doi: 10.1038/sj.npp.1300642
Lewis DA, Moghaddam B. Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations. Arch Neurol. 2006;63:1372.
pubmed: 17030651
doi: 10.1001/archneur.63.10.1372
Nakazawa K, Jeevakumar V, Nakao K. Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. npj Schizophrenia. 2017;3:7.
pubmed: 28560253
pmcid: 5441533
doi: 10.1038/s41537-016-0003-3
Javitt DC. Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment. Annu Rev Pharmacol Toxicol. 2023;63:119–41.
pubmed: 36151052
doi: 10.1146/annurev-pharmtox-051921-093250
Chang C-H, Lane H-Y, Tseng P-T, Chen S-J, Liu C-Y, Lin C-H. Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. J Psychopharmacol. 2019;33:436–48.
pubmed: 30730250
doi: 10.1177/0269881118822157
Wu Q, Huang J, Wu R. Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia. Front Neurosci. 2021;15:641047.
pubmed: 33912003
pmcid: 8072017
doi: 10.3389/fnins.2021.641047
Tsai GE, Lin P-Y. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16:522–37.
pubmed: 19909229
doi: 10.2174/138161210790361452
Javitt DC. Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet? Schizophrenia Bull. 2012;38:911–3.
doi: 10.1093/schbul/sbs100
Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull. 2010;83:108–21.
pubmed: 20417696
pmcid: 2941541
doi: 10.1016/j.brainresbull.2010.04.006
Hashimoto K. Glycine transporter-1: a new potential therapeutic target for schizophrenia. Curr Pharm Des. 2011;17:112–20.
pubmed: 21355838
doi: 10.2174/138161211795049598
D’Souza DC, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH, et al. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biol Psychiatry. 2018;84:413–21.
pubmed: 29499855
pmcid: 6068006
doi: 10.1016/j.biopsych.2017.12.019
Ohnuma T, Arai H. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:29–39.
doi: 10.1016/j.pnpbp.2010.08.027
Kim M-S, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map of the human proteome. Nature. 2014;509:575–81.
pubmed: 24870542
pmcid: 4403737
doi: 10.1038/nature13302
Xia M, Liu Y, Figueroa DJ, Chiu C-S, Wei N, Lawlor A-M, et al. Characterization and localization of a human serine racemase. Mol Brain Res. 2004;125:96–104.
pubmed: 15193426
doi: 10.1016/j.molbrainres.2004.03.007
Morgan C, Dazzan P, Lappin J, Heslin M, Donoghue K, Fearon P, et al. Rethinking the course of psychotic disorders: modelling long-term symptom trajectories. Psychological Med. 2022;52:2641–50.
doi: 10.1017/S0033291720004705
Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus. Am J Psychiatry. 2005;162:441–9.
pubmed: 15741458
doi: 10.1176/appi.ajp.162.3.441